Want to see BCAB full AI Analyst Report?
BCAB Stock Chart & Stats
$3.14
$0.00(0.00%)
At close: 4:00 PM EDT
$3.14
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.07 - $71.50
Previous CloseN/A
Volume9.08K
Average Volume (3M)16.10K
Market Cap
$2.26M
Enterprise Value$11.20M
Total Cash (Recent Filing)$1.54M
Total Debt (Recent Filing)$5.86M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.45
Shares Outstanding1,666,100
10 Day Avg. Volume6,189
30 Day Avg. Volume16,103
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.92
Price to Sales (P/S)16.70
P/FCF Ratio-0.69
Enterprise Value/Market Cap4.96
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit1.32
Enterprise Value/Ebitda-0.35
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp TTM revenue rebound indicates that BioAtla is generating more commercial or collaboration-related activity than in the prior period. If this improvement persists, it could broaden funding options and provide a stronger base for advancing its oncology pipeline, although profitability remains unresolved.
Improved Cash DisciplineCash burn has improved materially from the prior year, suggesting better expense control and/or working-capital dynamics. Lower operating outflows can extend the company’s available funding runway and reduce near-term capital pressure, even though BioAtla still requires external financing to support ongoing operations.
Expanded Funding AccessThe expanded standby equity facility gives BioAtla discretionary access to substantially more capital than its prior arrangement, supporting continued clinical and corporate activity. While equity draws can dilute shareholders, the facility improves financing flexibility for a company with persistent cash needs.
Bears Say
Negative EquityNegative stockholders’ equity signals a severely weakened capital base and limits financial flexibility. Declining assets alongside negative equity may make it harder to absorb setbacks, secure conventional funding, or sustain operations without additional equity issuance or other external capital.
Persistent UnprofitabilityBioAtla remains far from breakeven despite the revenue rebound, with substantial net losses and negative operating economics. Continued losses constrain internally generated funding, increase dependence on financing, and make future clinical development more vulnerable to capital availability and execution risk.
Nasdaq DelistingThe confirmed move from Nasdaq to OTC Markets is a structural setback for the company’s public-market position. Reduced exchange access can limit investor participation and trading liquidity, potentially complicating future capital raises and making equity-based financing less efficient over time.
BioAtla News
BCAB FAQ
What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $1.07 and its highest was $71.50 in the past 12 months.
What is BioAtla’s market cap?
BioAtla’s market cap is $2.26M.
When is BioAtla’s upcoming earnings report date?
BioAtla’s upcoming earnings report date is Nov 18, 2026 which is in 26 days.
How were BioAtla’s earnings last quarter?
BioAtla released its earnings results on Aug 06, 2026. The company reported $0.272 earnings per share for the quarter.
Is BioAtla overvalued?
According to Wall Street analysts BioAtla’s price is currently Overvalued.
Does BioAtla pay dividends?
BioAtla does not currently pay dividends.
What is BioAtla’s EPS estimate?
BioAtla’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioAtla have?
BioAtla has 1,666,100 shares outstanding.
What happened to BioAtla’s price movement after its last earnings report?
BioAtla reported an EPS of $0.272 in its last earnings report. Following the earnings report the stock price went up 0.15%.
Which hedge fund is a major shareholder of BioAtla?
Currently, no hedge funds are holding shares in BCAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioAtla
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
MAIA Biotechnology, Inc.
―
Ownership Overview
26.98% Insiders
11.77% Mutual Funds
1.02% Other Institutional Investors
60.23% Public Companies and
Individual Investors